Zacks Investment Research upgraded shares of PDI INC (PDII) from NEUTRAL to OUTPERFORM on May 16, 2013, with a target price of $5.10.
PDI, Inc. is a leading and rapidly growing contract sales organization, providing customized product detailing programs and other marketing and promotional services to the United States pharmaceutical industry. They are engaged by their clients on a contractual basis to design and implement product detailing programs for both prescription and OTC pharmaceutical products. Such programs typically include three phases: design, execution and assessment.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
To get a free copy of the research report on PDI INC (PDII),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment